| Abstract: | Datamonitor's Tanox, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. Tanox, Inc. - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
Tanox is a biopharmaceutical company focused on discovering and developing therapeutic monoclonal antibodies that influence or are derived from the immune system. The company's therapeutic emphasis is on the areas of immunology (asthma/allergy and autoimmune diseases), infectious diseases, and oncology. Tanox is headquartered in Houston, Texas and employed 200 people as of December 2006. The company recorded revenues of $56 million during the fiscal year ended December 2006, an increase of 24.4% over 2005. The operating loss of the company was $11 million during fiscal year 2006, an improvement of 55% over 2005. The net loss in fiscal year 2006 was $3 million, an improvement of 87% over 2005.
Scope of the Report
- Provides all the crucial information on Tanox, Inc. required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting Tanox, Inc. in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of Tanox, Inc.
-Data is supplemented with details on Tanox, Inc. history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Tanox, Inc.
Reasons to Purchase
- Support sales activities by understanding your customers' businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors' business structure, strategy and prospects
- Obtain the most up to date company information available
|
| Brief Excerpt: | ...Tanox is a biophar maceutical compan y f ocused on disco vering and de veloping ther apeutic monoclonal antibodies that influence or are der ived from the imm une system. The compan y s ther apeuticemphasis is on the areas of imm unology (asthma/allergy and autoimm une diseases), inf ectiousdiseases, and oncology .Tanox is headquar tered in Houston, Texas and emplo ys appro ximately 200 people .The compan y recorded re venues of $56 million dur ing the fiscal y ear ended December 2006, an increase of 24.4% o ver 2005. The oper ating loss of the compan y w as $11 million dur ing fiscal y ear2006, an impro vement of 55% o ver 2005. The net loss in fiscal y ear 2006 w as $3 million, an improvement of 87% o ver 2005. ...
|
